Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.

Ashida K, Iwakiri K, Hiramatsu N, Sakurai Y, Hori T, Kudou K, Nishimura A, Umegaki E.

World J Gastroenterol. 2018 Apr 14;24(14):1550-1561. doi: 10.3748/wjg.v24.i14.1550.

2.

Evaluation and management of Non-variceal upper gastrointestinal bleeding.

Samuel R, Bilal M, Tayyem O, Guturu P.

Dis Mon. 2018 Jul;64(7):333-343. doi: 10.1016/j.disamonth.2018.02.003. Epub 2018 Mar 7. Review.

PMID:
29525375
3.

Contributions From Gastroenterology: Acid Peptic Disorders, Barrett's Esophagus and Eosinophilic Esophagitis.

Souza RF, Rubenstein JH, Kao JY, Hirano I.

Gastroenterology. 2018 Apr;154(5):1209-1214. doi: 10.1053/j.gastro.2017.12.023. Epub 2018 Mar 8. No abstract available.

PMID:
29524399
4.

Comparison of the Effects of Vonoprazan and Lansoprazole for Treating Endoscopic Submucosal Dissection-Induced Artificial Ulcers.

Hirai A, Takeuchi T, Takahashi Y, Kawaguchi S, Ota K, Harada S, Kojima Y, Tominaga K, Tokioka S, Higuchi K.

Dig Dis Sci. 2018 Apr;63(4):974-981. doi: 10.1007/s10620-018-4948-0. Epub 2018 Feb 21.

PMID:
29464587
5.

Rise and fall of peptic ulceration: A disease of civilization?

Roberts-Thomson IC.

J Gastroenterol Hepatol. 2018 Jul;33(7):1321-1326. doi: 10.1111/jgh.14090. Epub 2018 Mar 12. Review.

PMID:
29319200
6.

First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease.

Liang CM, Kuo MT, Hsu PI, Kuo CH, Tai WC, Yang SC, Wu KL, Wang HM, Yao CC, Tsai CE, Wang YK, Wang JW, Huang CF, Wu DC, Chuah SK; Taiwan Acid-Related Disease Study Group.

World J Gastroenterol. 2017 Dec 21;23(47):8395-8404. doi: 10.3748/wjg.v23.i47.8395.

7.

Estrogen-Dependent Nrf2 Expression Protects Against Reflux-Induced Esophagitis.

Torihata Y, Asanuma K, Iijima K, Mikami T, Hamada S, Asano N, Koike T, Imatani A, Masamune A, Shimosegawa T.

Dig Dis Sci. 2018 Feb;63(2):345-355. doi: 10.1007/s10620-017-4885-3. Epub 2017 Dec 27.

PMID:
29282639
8.

Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases.

Yang X, Li Y, Sun Y, Zhang M, Guo C, Mirza IA, Li YQ.

Dig Dis Sci. 2018 Feb;63(2):302-311. doi: 10.1007/s10620-017-4866-6. Epub 2017 Dec 27. Review.

PMID:
29282636
9.

Pharmacological interventions for stress ulcer prophylaxis in critically ill patients: a mixed treatment comparison network meta-analysis and a recursive cumulative meta-analysis.

Sridharan K, Sivaramakrishnan G, Gnanaraj J.

Expert Opin Pharmacother. 2018 Feb;19(2):151-158. doi: 10.1080/14656566.2017.1419187. Epub 2017 Dec 22. Review.

PMID:
29271262
10.

Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.

Kawai T, Oda K, Funao N, Nishimura A, Matsumoto Y, Mizokami Y, Ashida K, Sugano K.

Gut. 2018 Jun;67(6):1033-1041. doi: 10.1136/gutjnl-2017-314852. Epub 2017 Dec 1.

11.

Influence of national centralization of oesophagogastric cancer on management and clinical outcome from emergency upper gastrointestinal conditions.

Markar SR, Mackenzie H, Wiggins T, Askari A, Karthikesalingam A, Faiz O, Griffin SM, Birkmeyer JD, Hanna GB.

Br J Surg. 2018 Jan;105(1):113-120. doi: 10.1002/bjs.10640. Epub 2017 Nov 20.

PMID:
29155448
12.

Treatment Strategy for Standard-Dose Proton Pump Inhibitor-Resistant Reflux Esophagitis.

Iwakiri K.

J Nippon Med Sch. 2017;84(5):209-214. doi: 10.1272/jnms.84.209. Review.

13.

A new paradigm for GERD pathogenesis. Not acid injury, but cytokine-mediated inflammation driven by HIF-2α: a potential role for targeting HIF-2α to prevent and treat reflux esophagitis.

Souza RF, Bayeh L, Spechler SJ, Tambar UK, Bruick RK.

Curr Opin Pharmacol. 2017 Dec;37:93-99. doi: 10.1016/j.coph.2017.10.004. Epub 2017 Nov 5. Review.

PMID:
29112883
14.

Urinary incontinence is associated with the development of peptic ulcers in adult women: Data from the KNHANES IV.

Choi JB, Yoon BI, Han KD, Hong SH, Ha US.

Medicine (Baltimore). 2017 Oct;96(43):e8266. doi: 10.1097/MD.0000000000008266.

15.

Nonalcoholic Fatty Liver Disease Is Associated with Increased Risk of Reflux Esophagitis.

Yang HJ, Chang Y, Park SK, Jung YS, Park JH, Park DI, Cho YK, Ryu S, Sohn CI.

Dig Dis Sci. 2017 Dec;62(12):3605-3613. doi: 10.1007/s10620-017-4805-6. Epub 2017 Oct 23.

PMID:
29063416
16.

Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study.

Mizokami Y, Oda K, Funao N, Nishimura A, Soen S, Kawai T, Ashida K, Sugano K.

Gut. 2018 Jun;67(6):1042-1051. doi: 10.1136/gutjnl-2017-314010. Epub 2017 Oct 7.

17.

Supplemental Content

Loading ...
Support Center